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1. Introduction 
Menorrhagia, defined as regular but heavy menstrual bleeding of more than 80 ml from a 
secretory endometrium is a common disorder. The prevalence is between 9% and 28% of 
women aged 16-45 years and increases with age.1 Approximately 30% of patients referred 
for gynaecological treatment are for menorrhagia and half of these women have a 
hysterectomy within 5 years if conservative treatment (e.g. contraceptive pills, progestogens, 
fibrinolytic inhibitors and prostaglandin inhibitors) fails. More than one third of these 
women undergoing hysterectomy have normal uteri.2,3  
In the USA, more than 600,000 hysterectomies are performed each year of which 30% for 
excessive menstrual bleeding. In the UK 40% of the 100,000 hysterectomies are performed 
for that reason. Idiopathic menorrhagia is the most common form of menorraghia when no 
underlying cause (e.g. uterine and endometrial abnormalities, systemic coagulation defects) 
can be found. Local defects in the haemostatic mechanism in the endometrium are most 
probably at the origin of the disorder such as an increased fibrinolytic activity or an 
imbalance in the different types of prostaglandins.4 
When menstrual blood loss exceeds 80 ml, the incidence of anaemia (haemoglobin less than 
12 g/dl) is increased significantly.5 Anaemia is one of the most widespread, and most 
neglected, nutritional deficiency diseases in the world today.6 Iron deficiency with depletion 
of iron stores and/or anaemia predisposes the women to ill health and disease. In addition, 
women with menorrhagia are often prevented from leading normal lives causing severe 
social embarrassment and repudiation by the partner. 
In recent years, new less invasive treatment options have been developed.7 Endometrial 
ablation techniques and classical endometrial resection have their value but are costly 
although significantly cheaper than hysterectomy. They are also irreversible. Second 
generation endometrial ablation techniques have fewer complications, are quicker and they 
seem to be more suitable for local anaesthesia than the first generation techniques. 
The intrauterine system releasing 20 μg of levonorgestrel (Mirena® LNG-IUS) has shown a 
dramatic decrease in menstrual blood loss in nearly all women and amenorrhoea in up to 
20% or more due to profound endometrial atrophy.8,9,10  
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The present report reviews the reduction of menstrual flow following insertion of the Femilis® 
LNG-IUS, a new T-shaped hormone-releasing IUS, releasing 20 μg of LNG/day. The report 
also evaluates other menstrual blood loss (MBL) studies, using the same drug delivery 
technology for the release of LNG, in which the effect on MBL was assessed with a frameless 
LNG-IUS, releasing only 14 μg of LNG/day, instead of 20 μg of LNG/day with the framed 
LNG-IUS. The evaluation is based on 6 clinical studies of which most of them were reported 
elsewhere.11,12,13,14,15 The use of the LNG-IUS as first option treatment of menorrhagia or heavy 
menstrual bleeding is discussed, including for the treatment of iron deficiency anaemia. 
2. Materials and methods 
2.1 Description of the T-LNG (Femilis®) IUS (Fig. 1) and the frameless FibroPlant®-LNG 
IUS (Fig. 2) 
The T-LNG-IUS (Femilis®, Contrel Drug Delivery Research, Belgium) has a 3-cm long and 
2.4-mm wide fibrous delivery system, consisting of a LNG-ethylene vinyl acetate (EVA) core 
and an EVA rate-controlling membrane that releases approximately 20 g of LNG daily. The 
drug compartment is provided with a crossarm fixed to the upper part of the drug delivery 
rod. The total length of the crossarm is 28 mm. The polyethylene crossarm contains 22% 
barium sulphate to render it radiopaque. The single tail is made of a 00 gauge 
polypropylene. 
 
 
 
Fig. 1. Femilis®  
The FibroPlant® LNG-IUS (Contrel Drug Delivery Research, Belgium) consists of a fibrous 
delivery system of 3-cm long and 1.2 mm in diameter that releases 14 g of LNG daily. The 
fibrous delivery system is fixed to an anchoring filament by means of a metal clip positioned 
1 cm from the anchoring knot. The anchoring knot at the proximal end of the thread is 
implanted into the myometrium of the uterine fundus using an insertion instrument, thus 
permanently securing the implant in the uterine cavity.   
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Fig. 2. FibroPlant® 
In vitro studies show that the rate of LNG-release is constant over several years (zero-order), 
except for the first two months of use, and is similar to the in vitro release rate of the Mirena® 
LNG-IUS. The duration of release is at least five years with the Femilis® LNG-IUS and at least 
three years with the FibroPlant® LNG-IUS. The in vitro release studies and other 
pharmacological analyses were conducted in collaboration with the Polymer Research Group, 
Department of Chemistry, University of Ghent, Ghent, Belgium and with the Analytical 
Pharmaceutical Chemistry of the Department of Pharmacy, University of Liège, Belgium. 
2.2 Insertion technique (Fig. 3 and Fig. 4) 
Femilis® 
The T-LNG-IUS (Femilis®) is inserted using the 'push-in' technique. Notably, upon entering 
the uterine cavity the crossarm unfolds immediately, thus minimising the risk of perforation.  
 
       
    Step 1    Step 2     Step 3   
Fig. 3. Insertion procedure of Femilis®. 
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FibroPlant®  
The anchoring knot at the proximal end of the thread is implanted into the myometrium of the 
uterine fundus using the standard GyneFix® insertion technique, thus permanently securing 
the implant in the uterine cavity. The stainless steel metal clip allows ultrasound and X-ray 
visibility of the system thus enabling correct location of the system in the uterine cavity, both 
at insertion and at follow-up. The fibrous delivery system is also visible on ultrasound.  
When compared with “framed” drug delivery systems such as the Mirena® and Femilis® 
LNG-IUS, the FibroPlant® LNG-IUS will be seen to have no frame. It is, therefore, 
completely flexible, with the ability to adapt to uterine cavities of every size and shape. 
 
 
 
 
Fig. 4. Insertion procedure of FibroPlant® is identical with the insertion procedure of the 
frameless GyneFix® copper-releasing IUD (See video insertion on www.wildemeersch.com). 
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2.3 Study population and menstrual blood loss assessment techniques  
Study 1: Femilis® in women with and without idiopathic menorrhagia (assessed by the 
visual menstrual score technique): Women less than 48 years of age at study enrollment 
with normal and with heavy menstrual periods were admitted into the study. Women with 
significant fibromyomas (>3 cm), or other uterine pathology, were excluded form the study. 
Women were followed-up for at least 12 months. 
A visual assessment technique was used as described by Janssen.3 Information on menstrual 
bleeding was obtained by interview retrospectively using a pictorial chart to describe the 
degree to which the sanitary wear was soiled. A score was calculated by multiplying the 
number of slightly, moderately and heavily soiled pads and tampons by one, five and 20 for 
pads and one, 5 and 10 for tampons, respectively, according to their degree of staining (Fig. 
5). The visual assessment technique does not yield an exact flow in ml, but, in practice, the 
sensitivity and specificity is reasonably high and superior to a women’s subjective 
assessment of MBL. For purposes of evaluating the effect of treatment, the visual assessment 
technique is highly practical compared with the quantitative method, described below, as 
women no longer have to submit sanitary wear to the laboratory. 
 
 
Fig. 5. Pictorial chart for the evaluation of menstrual blood loss. 
Study 2: Femilis® in women with and without heavy menstrual bleeding (HMB) (assessed 
by the quantitative alkaline haematin technique): 14 Brazilian women participated in this 
menstrual blood loss study (ongoing study). In this study, 6 months results are available in 
13 of them. MBL was quantified according to the technique first described by Hallberg and 
Nilsson16, adapted by Shaw17 and modified by Newton18 before insertion (baseline controls) 
of the IUS and after 3, and 6 months. Women were instructed to carefully collect their 
menstrual tampons and bring them to the laboratory in opaque plastic bags as soon as 
bleeding ended, as described previously.19 Serum ferritin was also measured at the same 
intervals as above. 
Study 3: FibroPlant® LNG-IUS in women with normal and heavy menstruation (assessed by 
the quantitative alkaline haematin technique): Menstrual blood loss studies were conducted 
in 40 Brazilian FibroPlant® LNG users with normal and heavy menstrual bleeding. Women 
were followed-up for at 3, 6, 12 and 24 months. MBL was quantified according to the 
technique described above. Serum ferritin was also measured at the same intervals as above. 
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Study 4: FibroPlant® LNG-IUS in women with idiopathic menorrhagia (visual menstrual 
score technique): The efficacy of the FibroPlant® LNG-IUS in reducing menstrual blood loss 
was tested in 12 Belgian women between 17 and 43 years of age suffering from idiopathic 
menorrhagia using the visual bleeding score (score >185) as described above. Women were 
followed-up for one year.  
Study 5: FibroPlant® LNG-IUS in women with idiopathic menorrhagia (visual menstrual 
score technique): Thirty-two insertions were performed in fertile women between 31 and 
51 years of age for the treatment of menorrhagia as well as for contraceptive purposes. 
Fifteen women were fitted with the FibroPlant® LNG-IUS immediately following removal 
of a copper-bearing IUD, the GyneFix® IUD, who developed excessive bleeding. To 
discriminate between menorrhagia and normal menstrual blood loss, women were 
evaluated using the visual assessment technique. The trial covers a period from a 
minimum of 1 month up to 23 months. 
Study 6: FibroPlant® LNG-IUS in women with menorrhagia associated with intrauterine 
fibroids (visual menstrual score technique): Fourteen insertions were performed in 
premenopausal women between 39 and 48 years of age for the treatment of menorrhagia in 
the presence of uterine fibroids. The effect on menstrual blood loss was evaluated using the 
visual assessment technique. Women were followed-up for at least 12 months. 
The use of the LNG-releasing IUS was approved by the Ethics Committee of the University 
of Ghent, Belgium and written informed consent was obtained. The quantitative MBL 
studies were approved by the Ethics Committee of the University of Juiz de Fora, Brazil. 
Prior to the insertion procedure, a medical history was taken and pelvic examination was 
carried out and the patient was checked for any clinical signs of sexually transmitted 
diseases. A transvaginal ultrasound examination was conducted to check for uterine 
pathology. In the fibroid MBL study (Study 6), the uterine fibroids were classified clinically 
and ultrasonographically as follows:  
Type I: single or multiple small intramural and subserosal fibroids (<3 cm). No evidence of 
submucosal fibroids. 
Type II: single or multiple intramural and subserosal fibroids (3-6 cm). No evidence of 
submucosal fibroids. 
Type III: single or multiple intramural and subserosal fibroids (>6 cm). No evidence of 
submucosal fibroids. 
Type IV: single or multiple intramural and subserosal fibroids. Suspicion or evidence of 
submucosal fibroids. 
Following insertion, a transvaginal ultrasound (TVU) was performed to locate the device in 
the uterus. An admission form was completed. 
2.4 Follow-up  
Women were followed-up at 1, (3), 6, and 12 months following insertion of the LNG-IUS 
and six-monthly or yearly thereafter. They were asked about their bleeding patterns and 
about side effects or adverse reactions. A gynaecological examination was performed as well 
as a transvaginal ultrasound to locate the device. A follow-up form was completed. 
2.5 Data collection, monitoring and analysis  
Data were recorded on standard pre-coded forms at admission, at each scheduled and 
unscheduled follow-up visit, and upon discontinuation from the study. All data were sent to 
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the data-coordinating centre at the Department of Medical Informatics and Statistics, 
University Hospital, Ghent, Belgium, for statistical data analysis, except the quantitative 
menstrual blood loss studies which was analysed at the Department of Statistics, Centro de 
Biologia da Reprodução, Universidade Federal Juiz de Fora, Brazil. 
The statistical significance in the studies using the visual assessment technique was 
calculated according to the Wilcoxon’s Signed Rank test, p<0.05 denoting significance. 
In the quantitative MBL study, all comparisons were made by means of the Chi-square test or 
the Student’s t-test, p<0.05 indicating significance. The coefficient of correlation was used to 
determine the strength of the relationship between the pairs of variables. 
The statistical significance in the studies using the visual assessment technique was 
calculated according to the Wilcoxon’s Signed Ranks test, p<0.05 denoting significance. 
3. Results 
Study 1: Femilis® LNG-IUS in women with and without idiopathic menorrhagia assessed by 
the visual menstrual score technique: The trial covers a period from a minimum of four 
months to more than 30 months of IUS use. MBL scores dropped significantly during the 
observation period in all women except one. The median menstrual score at baseline in 
women with normal menstrual bleeding (score <185) was 140 (range 80-160) and dropped to 
a median score of five (range 0-150) at the last follow-up, a decrease of 96%. In women with 
hemorrhagic bleeding (score ≥185) at baseline, menstrual flow dropped from a median score 
of 232 (range 185-450) at baseline to a median score of three (range 0-50) at the last follow-up 
visit, a decrease of 99%. Twenty women developed amenorrhoea (33%), 10 in the group of 
women with normal menstruation and 10 in those women with menorrhagia.  Most of the 
remaining women had strong oligomenorrhea requiring the use of a few panty-liners only. 
In one woman, MBL did not decrease for any apparent reason, thus requiring further 
evaluation (Table 1). 
 
 Total (n=60) Normal menses (n=28) Menorrhagia (n=32) 
 MS at 
insertion 
MS at last 
follow-up 
MS at 
insertion 
MS at last 
follow-up 
MS at 
insertion 
MS at last 
follow-up 
Median 200 5 140 5 232 3 
SD 87.5 21.5 25.7 29.8 75.7 9.4 
Minimum 80 0 80 0 185 0 
Maximum 450 150 160 150 450 50 
Wilcoxon matched-pairs signed-rank test: p<0.001 (highly significant).  
Table 1. Visual menstrual bleeding scores (MS) before and during treatment (observation 
from 4 months to 31 months) in 60 Femilis users (all women)  
Study 2: Femilis® in women with and without heavy menstrual bleeding (HMB) assessed by 
the quantitative alkaline haematin technique)(ongoing study): Menstrual blood loss reduced 
from a mean baseline menstrual volume of 47.6 ml to a mean volume of 1.1 ml after 6 
months. Ferritin values increased from a mean value of 74.6 ng/ml at baseline controls to a 
mean level of 93.5 ng/ml after 6 months of use. Amenorrhoea occurred in all women after 6 
months of use, except in one woman (Table 2). 
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MBL 
mean (N) 
FERRITIN 
mean (N) 
Baseline controls 47.6 (14) 74.6 (14) 
Interval 6 months 1.1 (13) 93.5 (13) 
MBL - in ml Ferritin - in ng/ml 
Amenorrhoea: all women, except one. 
Table 2. Menstrual blood loss quantification (ml) and serum ferritin levels (ng/ml) in 14 
Femilis-LNG users compared with controls (preliminary results; study ongoing) 
Study 3: FibroPlant® LNG-IUS in women with normal and excessive menstruation assessed 
by the quantitative alkaline haematin technique: Quantitative menstrual blood loss studies 
were conducted in 40 Brazilian FibroPlant® users with normal and heavy menstrual 
bleeding. Menstrual blood loss reduced from a mean baseline menstrual volume of 29.7 ± 
2.2 ml to a mean volume of 1.5 ± 2.8 ml after 24 months. Ferritin values increased from a 
mean baseline value of 31.1 ± 3.2 ng/ml at baseline controls of the LNG-IUS to a mean level 
of 72.5 ± 2.1 ng/ml after 24 months of use. Differences in menstrual volume and ferritin 
levels are highly significant (p<0.0005) (Table 3). Amenorrhoea occurred in 80% of women 
out of 40 after 24 months of use.  
 
 
MBL 
mean ± SD (N) 
HGB 
mean ± SD (N) 
FERRITIN 
mean ± SD (N) 
Baseline controls 29.7 ± 2.2 (40) 12.4 ± 0.9 (40) 31.1 ± 3.2 (40) 
Interval 3 months 3.3 ± 3.6 (39)* 12.5 ± 0.9 (39) 37.1 ± 2.8 (39)* 
Interval 6 months 2.0 ± 3.1 (40)* 12.5 ± 0.9 (40) 47.8 ± 2.2 (40)* 
Interval 12 months 1.7 ± 2.5 (39) * 12.4 ± 0.8 (40) 56.2 ± 2.1 (40) * 
Interval 24 months 1.5 + 2.8 (40)* 12.7 + 1.1 (40) 72.5 ± 2.1 (40)* 
MBL in ml HGB -  Ferritin in ng/ml 
* p<0.0005 Observation: due to skewed distribution MBL and Ferritin values were log transformed 
before calculations 
Amenorrhoea (months): 3: 18 users = 45%; 6: 27 users = 67.5%; 12: 28 users = 70%; 24: 32 users = 80% 
MBL: pre-insertion: mean 29.7 ± 2.2ml (variation: 3.6 – 90.0  ml) 
At 24 months: mean 1.5 ± 2.8ml (variation: 0 – 29.7ml)   
Table 3. Menstrual blood loss quantification (ml) and serum ferritin levels (ng/ml) in 40 
FibroPlant-LNG users compared with controls  
Study 4: FibroPlant® LNG-IUS in women with idiopathic menorrhagia assessed by the 
visual menstrual score technique: The results are presented in Table 4. All women 
reported a marked reduction in menstrual blood loss which started from the first 
menstrual period following insertion of the IUS. Bleeding reduced further over the next 
months until the 6th month. No amenorrhoea occurred. The difference in menstrual 
bleeding was highly significant (p=0.002) which resulted in a significant increase in 
ferritin levels (p=0.002).  
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 Before insertion at 12 months 
Median MS ± SD 325.0 ± 122.2 12.5 ± 42.8* 
Mean ferritin level ± SD 19.8 ±10.1 44.5 ± 22.2* 
Wilcoxon matched-pairs signed-ranks test: *p=0.002 (highly significant) 
Table 4. Visual menstrual bleeding scores (MS) and ferritin levels (ng/l) before and 
during treatment (observation period 12 months) in 12 FibroPlant® users with 
menorrhagia (score >185).  
Study 5: FibroPlant® LNG-IUS in women with idiopathic menorrhagia assessed by the visual 
menstrual score technique: All women reported greatly reduced bleeding (Table 5). The mean 
bleeding score before treatment was 338 (185-740) in the group with no prior IUD use and 368 
(185-890) in the group with prior IUD use, respectively, and dropped to a mean score of 70 
(range 5-210) in the 'no prior IUD use' group and to a mean score of 52 (3-150) in the 'prior IUD 
use' group, respectively after 1 to 23 months follow-up which is highly statistically significant 
(p<0.001). There was no statistical difference in bleeding scores before and during treatment 
between the two groups of women with or without prior copper IUD use.  
 
A. Before treatment 
 
 No prior IUD use Prior IUD use 
n  17 15 
Mean  337.9 368.0 
St. Dev.  139.2 172.0 
Median  324.2 328.8 
Minimum  185 185 
Maximum  740 890 
Mann-Whitney U-test: p=0.63 (NS) 
 
B. During treatment 
 
 No prior IUD use Prior IUD use 
n  17 15 
Mean  70.0 52.3 
St. Dev.  52.8 51.3 
Median  62.5 41.3 
Minimum  5 3 
Maximum  210 150 
Mann-Whitney U-test: p=0.31 (NS) 
Table 5. Analysis of the Visual Bleeding Scores comparison between the group with prior 
IUD use (n = 15) and the group with no prior IUD use (n = 17). A. Before treatment. B: 
During treatment 
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Study 6: Femilis® LNG-IUS in women with menorrhagia associated with intrauterine 
fibroids assessed by the visual menstrual score technique: All women reported greatly 
reduced bleeding, except one. In two women, the treatment failed although both reported 
reduced bleeding. One failure was due to the presence of a large endometrial polyp. This 
patient underwent hysterectomy. The other women had submucosal fibroids. She refused 
hysterectomy and is continuing treatment. In the other 12 patients, reduction of bleeding 
was apparent after one month of treatment and tended to decrease further over the next 
months to stabilize afterwards. The mean bleeding score before treatment was 465 (185-960) 
and dropped to a mean score of 100 (range 5-300) after treatment which is highly statistically 
significant (p<0.001) (Table 6). In 8 women, the bleeding reduced to very low scores.  
 
 
 Age 
VBS before 
treatment 
VBS during 
treatment 
Mean 45 455 100 
Std Deviation 3 210 85 
Median 45 410 71 
Range 39 - 49 185 - 960 5 – 300 
Table 6. Descriptive statistics: age and visual bleeding scores (VBS) before and during 
treatment 
4. Discussion and conclusion 
The intrauterine release of LNG alters the function of the endometrium. This phenomenon 
offers special benefits for users and a manner of local intrauterine therapy. 
The reduction of menstrual blood loss is based on the antiproliferative action of the LNG-
IUS on the endometrium. The morphology of the endometrium is considerably altered, 
showing massive decidualization of the stroma, atrophic glands, and sometimes atrophy of 
the whole functional layer.20 Normal endometrium during the menstrual cycle produces 
many highly active compounds (e.g., prostaglandins, estrogen, and estro-progestogen-
induced growth factors and other bioactive peptides). In the endometrium suppressed by 
LNG, the production of these compounds is down regulated. On the other hand, 
progestogen stimulates the synthesis of other factors such as prolactine receptor, 
cyclooxygenase-2, and insulin-like growth factor-binding protein-1.21,22 Furthermore, a 
significant increase in uterine artery resistance occurs in LNG-IUS users 1 year after 
insertion which might contribute in reducing menstrual blood flow with the LNG-IUS.23  
4.1 Treatment of idiopathic menorrhagia 
The Mirena® LNG-IUS, releasing 20 μg of LNG/day has been compared with other 
medication in the treatment of menorrhagia.24,25,26 Overall, the Mirena® LNG-IUS has been 
found to be more effective than conventional medication and treatment is also more 
economic. It was also found that the LNG-IUS was much more effective in reducing the 
mean MBL below the upper limit of normal MBL (<80 ml). When compared with 
transcervical endometrial resection (TCRE), both methods are equally effective. However, 
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endometrial destruction is not always complete. It could, therefore be beneficial to use the 
hormonal IUS in combination with endometrial destruction. The LNG-IUS, inserted just 
after the procedure, can be used to improve the results of endometrial resection. Maia et al.27 
reported the results of an interesting study. They investigated 106 women with HMB. After 
endometrial resection, the women were randomized into two groups, 53 women in each. 
Women in the treatment group were fitted with Mirena®. In this group, amenorrhoea was 
achieved in 72% of cases after 3 months, in 89% after 6 months and in 100% after 1 year. In 
the resection-only group, the corresponding numbers were 19%, 17% and 9%, and in this 
group, 19% of the women underwent a second resection.  
Endometrial resection requires a specialist with endoscopic skills, and to be safe, well-
equipped operation facilities. Endometrial ablation is associated with a higher risk of 
perioperative and long-term complications than use of a LNG-IUS. The cost over 5 years is 
high because of recurrences and hysterectomies. These are not problems in connection with 
the LNG-IUS. However, the most important difference between operative therapy and use 
of the LNG-IUS is that fertility is lost after the former treatment. On the other hand, women 
at risk for pregnancy and undergoing endometrial ablation should use effective 
contraception or consider being surgically sterilized, whereas the LNG-IUS provides 
effective contraception, and treats heavy menstrual bleeding. 
In comparison with hysterectomy, morbidity (readmission for serious adverse events) is 
much higher in women undergoing surgery. In a recently conducted nationwide study in 
the UK, it was found that hysterectomy for benign indications, irrespective of surgical 
technique, increases the risk for subsequent stress-urinary-incontinence surgery.28 In 
addition, the overall costs of surgery are about three times higher in women undergoing 
hysterectomy than in women using the Mirena® LNG-IUS.29  
A recent Cochrane review on surgical versus medical therapy for heavy menstrual bleeding 
concluded that the Mirena® LNG-IUS provides a better alternative to surgery than oral 
medication.30 Although hysterectomy is a definite treatment for heavy menstrual bleeding, it 
does not improve the overall quality of life significantly more than the LNG-IUS and can 
cause serious complications. Questions remains, however, about the long term clinical 
effectiveness of all the treatments; evidence from trials with longer term follow-up (four 
years or more) is limited. The LNG-IUS, in particular, versus alternative forms of surgical 
treatment requires further research. 
The MBL studies reviewed in this report conducted with the T-shaped (Mirena®-like) LNG 
IUS, Femilis®, releasing 20 μg of LNG/day, and with the “frameless” FibroPlant® LNG- IUS, 
releasing 14 μg of LNG/day, in women with a normal menstrual pattern and in women 
with idiopathic menorrhagia, found a similar drastic reduction in MBL as in the studies 
conducted with the Mirena® LNG-IUS. Some of these studies are conducted over more than 
5 years without recurrence of episodes of heavy periods. 
4.2 Abnormal uterine bleeding in women certain subgroups of women 
4.2.1 Abnormal uterine bleeding in women with hemostatic disorders or using 
anticoagulant therapy 
The most common underlying bleeding disorder is von Willebrand’s disease, which occurs 
in only 1% to 2% of the general population but in approximately 13% of women with 
excessive menstrual bleeding. The diagnosis of von Willebrand’s disease in healthy females 
with excessive menses is a true challenge to the gynaecological community. In such women, 
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bleeding disorders might be “mild,” with menorrhagia being the only apparent clinical 
impact of the disorder. The diagnosis of von Willebrand’s disease and other bleeding 
disorders might have an important impact on a woman and her family. It should be 
emphasized that gynaecologists should consider causes of excessive menstruation that are 
“outside the uterus” and that some pathology, such as subserosal or intramural 
leiomyomas, might indeed be asymptomatic. For women who are diagnosed with von 
Willebrand’s disease and heavy menstrual bleeding, there is likely a benefit from the 
provision of the LNG-IUS.31,32 Thus, the LNG-IUS appears to be an effective long-term 
treatment for HMB in women with inherited bleeding disorders (IBDs) in general. Also 
women having anticoagulant therapy could benefit from the LNG-IUS.33,34 
4.2.2 Excessive menstrual bleeding in adolescents 
Menstrual disorders are common in adolescent girls in general. It commonly begins at 
menarche and can present acutely. This is usually secondary to anovulatory cycles caused 
by the immaturity of the hypothalamic-pituitary-ovarian axis. The condition adversely 
affects the QOL of affected adolescents. It can cause significant distress and discomfort in 
adolescent girls. It also has major health implications, such as iron deficiency anaemia and 
the need for hospitalization and blood transfusion in severe cases. It can affect their school 
attendance and performance. Treatment options include tranexamic acid, the combined oral 
contraceptive pill, the LNG-IUS, and specific hemostatic therapies, such as desmopressin 
and clotting factor replacement, if associated with inherent bleeding disorders.35 These 
conservative treatment options should seek to avoid surgical intervention. When the LNG-
IUS is selected, care should be taken to insert a device that fits in the usually small uterine 
cavity of these young women to maximize acceptance and continuation of use. 
4.3 Heavy bleeding in intrauterine device users 
Copper-releasing intrauterine devices may induce longer, heavier, and more painful 
periods. Pain and heavy menstrual bleeding are common reasons for discontinuing use of 
an intrauterine device within the first year. A recent Cochrane review evaluated data from 
15 randomised controlled trials investigating the effect of NSAIDs on treatment or pre-
vention of pain and bleeding due to an intrauterine contraceptive device.36 Data from 
prevention trials were inconsistent. In otherwise asymptomatic women NSAIDs reduced 
pain or bleeding (or both) in three studies, did not differ from placebo in two studies, and 
reduced bleeding but not pain in another. A large trial of 2019 first time users in Chile did 
not support the prophylactic use of ibuprofen compared with placebo to reduce rates of 
removal of devices because of pain or bleeding.37 Pain and/or abnormal, erratic or heavy 
menstrual bleeding is often caused by disharmony between the IUD and the uterine cavity 
(Figure 6). Recent 3-D sonography studies compared women with abnormally and those 
with normally located IUDs with respect to their indication for sonography and found that 
the proportion of patients whose principal indication for sonography was bleeding, pain or 
bleeding and pain were significantly greater in those with an abnormally located IUD, 
including imbedded IUDs, compared with those whose IUD was not located abnormally on 
3-D sonography.38,39 Clinical trials demonstrated, for the first time, the absence of a 
significant effect of the tiny GyneFix® IUD on menstrual blood loss due to its very small size 
and optimal harmony with the uterine cavity, leaving the cavity totally undisturbed.40 This 
is important since abnormal bleeding and pain are the two major reasons for IUD 
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discontinuation.41 In a Swedish study in CuT380A IUD users an increase in MBL was shown 
which ranged between 50 and 60%.42 
 
     
 
     
Fig. 6. a) Paragard® IUD; b) 3-D sonography of Paragard® in small uterine cavity of which 
the left arm penetrates the uterine wall (courtesy of Dr. B. Benacerraf); frameless GyneFix® 
IUD in foam uterus; 3-D sonographic picture of GyneFix® in narrow uterine cavity (courtesy 
of Dr. S. Jandi). 
Many women can tolerate alterations in bleeding with copper-releasing IUDs. However, if 
the menstrual bleeding disturbances are causing discomfort or are too heavy, removal of the 
IUD will be requested. Of great importance are the long-term implications of excessive 
menstrual blood loss on iron stores with progressive development of iron depletion in IUD 
users, especially in developing country regions where the recipients of this contraceptive 
method are commonly of high parity and poor nutritional status. Kivijarvi et al. found 
clinical anaemia in 10% of users of copper IUDs after 12 months exposure and iron 
deficiency, as judged by the ferritin levels, could be demonstrated in 20%.43 The effect of 
a
c
b
c d
b
www.intechopen.com
 Amenorrhea 
 
104 
MBL on iron stores was studied in Sweden which showed that the prevalence of iron 
deficiency anaemia doubled when MBL was between 60 and 80 ml and tripled when MBL 
was greater than 80 ml.43,44 A significant drop in haemoglobin levels already occurs in 
women with an average menstrual blood loss of 66 ml over 12 menstrual cycles of IUD 
use.45 The vulnerability of women in certain less developing parts of the world is indicated 
by the presence of iron deficiency in as many as 50% of women using an IUD, if a dietary 
supplement is not provided. It is probable that about 10% of women using an IUD risk 
secondary anaemia, especially those who bleed more than 80 ml per period. It has been 
suggested that an increased risk of iron deficiency exists even with a 40 ml blood loss.46 
The main challenge of intrauterine contraceptive developers is to minimize menstrual side 
effects of IUDs without affecting efficacy and to reduce menstrual blood loss to enhance 
the health benefits of the method. Especially for women with low body iron stores, there 
is an order of preference for IUD use to minimize menstrual blood loss. The choice should 
first be a progestogen-releasing IUS, then a copper IUD which has the least effect on 
menstrual bleeding. 
4.4 Treatment of menorrhagia associated with uterine fibroids 
Although the main therapeutic approach in women with uterine leiomyomata remains 
surgery, several conservative medical treatments have been tested. The role of GnRH 
agonists in the treatment of uterine leiomyomas is limited as most leiomyomas return to 
their initial size within 4 months of cessation of the therapy.47 GnRH agonists are mainly 
useful when used preoperatively to reduce the myoma size. 
Treatment of leiomyomas with progestogens and antiestrogens is based on the suggestion 
that leiomyomas are ovarian steroid dependent. The result, however, of progesterone have 
been poor and no studies have ever demonstrated the benefit of progesterone alone.48 
Tamoxifen inhibits breast cancer cells by its great affinity for the estrogen receptor. 
However, on the endometrial level tamoxifen may induce endometrial hyperplasia and 
endometrial cancer. While acting as an anti-oestrogen on the breast, tamoxifen has an 
opposite effect on the endometrium as it acts as a partial estrogen agonist, rather than as 
an antagonist.49 
To avoid systemic systems, local therapy might optimize innovative approaches. Local 
therapy has been widely used for contraception but it has not been used to control 
leiomyoma symptoms. Intrauterine treatment might target myoma specific symptoms better 
and be more effective in reducing pelvic pressure due to the size of the tumor, and abnormal 
uterine bleeding. The success rate is less consistent especially in the presence of submucosal 
fibroids. The reduction in MBL in women with uterine fibroids was also confirmed in two 
recently published studies using the Mirena® LNG-IUS.50,51 The results are similar with 
those reported by Wildemeersch et al.12 Haemoglobin and ferritin levels increased 
significantly over 1 year of use. It appears that in women with a normal uterine cavity, a 
success rate in terms of a significant reduction in MBL close to 100% can be guaranteed.  
The study conducted in women with significant fibroids (Study 6) confirms the previous 
results in women with menorrhagia with normal uteri. Twelve out of 14 women admitted in 
the study were successfully treated. The treatment, however, was unsuccessful in two 
women due to abnormalities present in the uterine cavity. It follows that, if reduction of 
bleeding cannot be obtained, the presence of intracavitary pathology (e.g. submucous 
fibroids, polyps) should be suspected. Treatment failure in the presence of submucosal 
fibroids is caused by blood vessels which proliferate in the endometrium overlying the 
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fibroid which can cause 'heavy' bleeding. These vessels are not present in subserosal 
fibroids. This study does not suggest that LNG-release in the uterine cavity is capable of 
reducing the size of the myomas in women at reproductive age. The LNG-IUS significantly 
reduces uterine volume in women with menorrhagia with and without leiomyoma. The 
absence of significant reduction in the volume of leiomyomas was confirmed by others.52 
Decrease in size of leiomyomas is usually seen in menopausal women. In a study conducted 
by Inki and colleagues, no marked change was noted in the mean size of the fibroids. 
Further evaluation revealed that some had grown and some had shrunk.53 Maruo and 
colleagues suggested that progesterone may have dual actions on uterine leiomyoma 
growth. By up regulating some endometrial proteins and down regulating tumor necrosis 
factor α, progesterone can stimulate leiomyoma growth, and by down regulating insulin-
like growth factor-1 expression, inhibit growth.54 Local autocrine or paracrine growth factor 
balance around each fibroid may define the direction of the effect. 
Local delivery of other drugs such as mifepristone or another progesterone receptor 
modulator (PRM), with strong antiprogestogen activity and antiestrogenic effect at the 
endometrial level, may be more suitable to reduce the size of the fibroid tumors.  
An additional advantage of the LNG-IUS is the highly appeasing effect of the treatment in 
women with dysmenorrhoea. Wildemeersch and colleagues showed a highly beneficial 
effect in women with dysmenorrhoea, confirming other studies, conducted with the 
frameless LNG-IUS in women with primary and secondary dysmenorrhoea.55 
4.5 Treatment of anaemia due to heavy menstrual bleeding 
Excessive MBL (>80 ml) is the most common cause of iron deficiency anaemia in women.56 
Many women, especially in developing countries, start their reproductive years with 
inadequate iron stores. Because of the closely spaced pregnancies, they have little time to 
build up their haemoglobin levels.4 Each pregnancy makes them more vulnerable to serious 
ill health and death. A survey conducted by the World Health Organization reported a 19% 
prevalence rate of menorrhagia in 14 developing countries.57  
An immediate and cost-effective solution is to provide women with a progestogen-releasing 
device to minimize MBL, especially for women with low body iron stores which will result 
in improved haemoglobin and ferritin levels. The use of the LNG-IUS is, therefore, an 
economical and logical approach when compared with alternatives such as hysterectomy or 
endometrial ablation.6,25,58 The simultaneous provision of a long-acting and effective 
contraceptive may also be of substantial benefit to women.  
5. Conclusion 
We conclude with NICE (National Institute Clinical Excellence)59: 
Drug treatment 
“If history and investigations indicate that pharmaceutical treatment is appropriate and 
either hormonal or nonhormonal treatments are acceptable, treatments should be 
considered in the following order: 
 Levonorgestrel-releasing intrauterine system, provided long-term (at least 12 months) 
use is anticipated.  
 Tranexamic acid or non-steroidal anti-inflammatory drugs (NSAIDs) or combined oral 
contraceptives (COCs).  
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 Norethisterone (15 mg) daily from days 5 to 26 of the menstrual cycle, or injected long-
acting progestogens.” 
“If hormonal treatments are not acceptable to the woman, then either tranexamic acid or 
NSAIDs can be used.” 
Surgery 
“In women with heavy menstrual bleeding alone, with uterus no bigger than a 10-week 
pregnancy, endometrial ablation should be considered preferable to hysterectomy.” The 
report makes clear that hysterectomy should only be considered as a last option. 
Commenting at its launch, Mary Ann Lumsden, a consultant in gynecology and 
chairwoman of the NICE guidelines development group that produced the report, said: “In 
the early 1990s it was estimated that at least 60 percent of women presenting with heavy 
menstrual bleeding would have a hysterectomy to treat the problem, often as a first-line 
treatment and without discussion of any alternative options. This should now be rare as it is 
fundamental that all women with heavy periods know there is a range of treatment options, 
many of which don’t require surgery.” 
An additional advantage of the LNG-IUS is that it may also be beneficial in women with 
endometriosis, adenomyosis, fibroids and endometrial hyperplasia, conditions which are 
frequently associated with menorrhagia.60,61,62  
Most patients are likely to select a non-invasive treatment. Avoiding major surgery, 
combined with no hospitalization and quick recovery, are seen as major advantages of non-
invasive management. In women treated with the LNG-IUS, this device would be preferred 
over hysterectomy by 95% of the patients if the expected success rate were >50%.63 
Endometrial destruction is the second-line treatment for menorrhagia but it can be 
considered as the first-line treatment for patients in whom other forms of treatment are 
unsuitable or if the risks relating to surgery are high. The insertion of an LNG-IUS following 
endometrial resection, to increase the rate of amenorrhoea, may be interesting in some 
cases.27 The rationale is that up to 30% of patients need a subsequent procedure which can 
be avoided by the insertion of an LNG-IUS.  
Being an effective contraceptive, together with the strong reduction of MBL, makes it a 
very attractive method for many women in developed and developing countries. The 
simple and safe insertion procedure of the Femilis® LNG-IUS could be an added 
advantage for use by non-specialist providers such as nurses, midwives and general 
practitioners who are practicing in remote areas as many women lack access to specialized 
treatment in these areas. 
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